Alligator Bioscience AB Full Year 2016 Report
Summary · During the quarter were the company’s shares listed for trading on Nasdaq Stockholm Mid Cap. In connection with this were new shares issued that provided the company 350 000 TSEK before underwriting expenses. · The company's project portfolio has continued to develop according to plan including the start of dosing in a second phase I clinical trial that is done by Janssen Biotech. · The Board of Directors proposes that no dividend shall be paid for the year 2016. Conference call for investors, analysts and the mediaThe 2016 Financial Statement will be presented by